Last reviewed · How we verify
Pivamdinocillin (pivmecillinam)
Pivmecillinam works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
At a glance
| Generic name | pivmecillinam |
|---|---|
| Also known as | Selexid, Penomax, Selexid |
| Sponsor | Sykehuset i Vestfold HF |
| Drug class | pivmecillinam |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Imagine your body's cells are like houses, and the bacteria are like construction workers trying to build new houses. Pivmecillinam stops the construction workers from getting the materials they need, so they can't build new houses and the existing houses (bacteria) eventually die.
Approved indications
Common side effects
- Hydronephrosis
- Abdominal pain
- Blood creatinine increased
- Hyperammonaemic encephalopathy
Key clinical trials
- Prediction and Prevention of Bloodstream Infections After Kidney Transplantation (PHASE2)
- Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care (PHASE4)
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women. (PHASE4)
- Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis (PHASE4)
- Clinical Trial of Pivmecillinam Hydrochloride Tablets in the Treatment of Uncomplicated Urinary Tract Infection (PHASE3)
- Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs (PHASE3)
- Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. (PHASE4)
- Treating Pyelonephritis an Urosepsis With Pivmecillinam (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pivamdinocillin CI brief — competitive landscape report
- Pivamdinocillin updates RSS · CI watch RSS
- Sykehuset i Vestfold HF portfolio CI